查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1422888

2024-2032 年按技術（流式細胞儀、聚合酶鏈反應、下一代定序等）、應用、最終用戶和地區分類的最小殘留疾病檢測市場

Minimal Residual Disease Testing Market by Technology (Flow Cytometry, Polymerase Chain Reaction, Next Generation Sequencing, and Others), Application, End User, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 141 Pages | 商品交期: 2-3個工作天內

價格

2023年，全球微小殘留疾病（MRD）檢測市場規模達21億美元。展望未來， IMARC Group預計到2032年市場規模將達到51億美元，2024-2032年複合年成長率（CAGR）為10.21% 。醫療保健產業的顯著成長、廣泛的研發 (R&D) 活動以及快速的技術進步是推動市場發展的一些關鍵因素。

微小殘留疾病（MRD）檢測是一種醫學檢測，用於檢測和監測接受癌症治療後患者體內可能殘留的少量癌細胞。它廣泛用於檢測多種不同類型的癌症，例如白血病、淋巴瘤、多發性骨髓瘤和一些實體腫瘤。 MRD 檢測採用高度靈敏的方法，包括細胞計數、聚合酶鏈反應 (PCR) 和新一代定序 (NGS)。它是監測癌症患者並幫助醫生做出更明智的治療決策的重要醫學測試。 MRD 檢測有助於早期發現疾病復發，提供更準確的治療反應評估，並透過識別患者、改善患者結果和增強客製化治療計劃來指導個人化治療計劃。

微小殘留疾病 (MRD) 檢測市場趨勢：

全球癌症盛行率不斷上升是推動市場成長的關鍵因素之一。 MRD 檢測是一種高度敏感的技術，廣泛用於檢測殘留癌細胞，有助於早期指示疾病復發，並有助於指導個人化治療計劃。與此一致的是，MRD 檢測作為一種診斷和監測工具，廣泛應用於始於造血組織或免疫系統細胞的血液癌症，有利於市場成長。此外，消費者對個人化醫療的偏好轉變，允許客製化治療計劃和監測，這是另一個成長誘導因素。除此之外，人工智慧(AI) 與MRD 測試的整合有助於識別模式、預測復發的可能性、提高診斷的準確性和有效性，並幫助臨床醫生就患者護理做出更明智的決策，從而提供了一種市場成長的動力。此外，擴大採用 NGS 技術來確定脫氧核糖核酸 (DNA) 或核糖核酸 (RNA) 的序列，以研究與疾病相關的遺傳變異，這為市場創造了積極的前景。此外，人們越來越認知到識別體內可能導致癌症的致癌物質的重要性，這正在推動市場成長。其他因素，包括醫療保健行業的顯著成長、廣泛的研發 (R&D) 活動以及 MRD 檢測項目領域投資的增加，預計將推動市場成長。

本報告回答的關鍵問題：

  • 迄今為止，全球微小殘留疾病（MRD）檢測市場表現如何，未來幾年將如何表現？
  • 全球微小殘留疾病（MRD）檢測市場的促進因素、限制因素和機會是什麼？
  • 每個促進因素、限制因素和機會對全球微小殘留疾病 (MRD) 檢測市場有何影響？
  • 主要區域市場有哪些？
  • 哪些國家代表了最具吸引力的微小殘留疾病 (MRD) 檢測市場？
  • 什麼是基於技術的市場分割？
  • 微小殘留疾病（MRD）檢測市場中哪一項技術最具吸引力？
  • 基於應用程式的市場區隔是什麼？
  • 微小殘留疾病（MRD）檢測市場中最有吸引力的應用是什麼？
  • 基於最終用戶的市場區隔是什麼？
  • 微小殘留疾病 (MRD) 檢測市場中哪一個對最終用戶最具吸引力？
  • 全球微小殘留疾病（MRD）檢測市場的競爭結構如何？
  • 全球微小殘留疾病（MRD）檢測市場的主要參與者/公司有哪些？

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 資料來源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球微小殘留疾病 (MRD) 檢測市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：依技術

  • 流式細胞儀
    • 市場走向
    • 市場預測
  • 聚合酶鍊式反應 (PCR)
    • 市場走向
    • 市場預測
  • 次世代定序 (NGS)
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 7 章：市場區隔：按應用

  • 血液系統惡性腫瘤
    • 市場走向
    • 關鍵環節
      • 白血病
      • 淋巴瘤
    • 市場預測
  • 實體腫瘤
    • 市場走向
    • 市場預測

第 8 章：市場區隔：依最終用戶

  • 醫院和專科診所
    • 市場走向
    • 市場預測
  • 診斷實驗室
    • 市場走向
    • 市場預測
  • 學術及研究機構
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 9 章：市場區隔：按地區

  • 北美洲
    • 美國
      • 市場走向
      • 市場預測
    • 加拿大
      • 市場走向
      • 市場預測
  • 亞太
    • 中國
      • 市場走向
      • 市場預測
    • 日本
      • 市場走向
      • 市場預測
    • 印度
      • 市場走向
      • 市場預測
    • 韓國
      • 市場走向
      • 市場預測
    • 澳洲
      • 市場走向
      • 市場預測
    • 印尼
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 歐洲
    • 德國
      • 市場走向
      • 市場預測
    • 法國
      • 市場走向
      • 市場預測
    • 英國
      • 市場走向
      • 市場預測
    • 義大利
      • 市場走向
      • 市場預測
    • 西班牙
      • 市場走向
      • 市場預測
    • 俄羅斯
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 拉丁美洲
    • 巴西
      • 市場走向
      • 市場預測
    • 墨西哥
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 中東和非洲
    • 市場走向
    • 市場細分：按國家/地區
    • 市場預測

第 10 章：促進因素、限制與機會

  • 概述
  • 促進要素
  • 限制
  • 機會

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 13 章：價格分析

第14章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Adaptive Biotechnologies Corporation
    • Arup Laboratories Inc.
    • Bio-Rad Laboratories Inc.
    • Guardant Health
    • Invivoscribe Inc.
    • Natera Inc.
    • NeoGenomics Laboratories Inc.
    • Sysmex Corporation
Product Code: SR112024A7248

Abstract

The global minimal residual disease (MRD) testing market size reached US$ 2.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 5.1 Billion by 2032, exhibiting a growth rate (CAGR) of 10.21% during 2024-2032. Significant growth in the healthcare industry, extensive research and development (R&D) activities and rapid technological advancements represent some of the key factors driving the market.

Minimal residual disease (MRD) testing is a medical test used to detect and monitor small amounts of cancer cells that may remain in a patient's body after undergoing cancer treatment. It is widely used to test a variety of different types of cancer, such as leukemia, lymphoma, multiple myeloma, and some solid tumors. MRD testing uses highly sensitive methods, including cytometry, polymerase chain reaction (PCR), and next-generation sequencing (NGS). It is an important medical test for monitoring cancer patients and helping doctors to make more informed treatment decisions. MRD testing helps in the early detection of disease recurrence, providing a more accurate assessment of treatment response and guiding personalized treatment planning by identifying patients, improving patient outcomes, and enhancing customized treatment planning.

Minimal Residual Disease (MRD) Testing Market Trends:

The increasing prevalence of cancer across the globe is one of the key factors driving the market growth. MRD testing is a highly sensitive technique that is widely used to detect residual cancer cells, which helps in an early indication of disease recurrence and helps guide personalized treatment planning. In line with this, the widespread adoption of MRD testing as a diagnostic and monitoring tool in hematological cancers that begin in blood-forming tissues or the cell of the immune system is favoring the market growth. Moreover, the shifting consumer preference toward personalized medicine that allows customized treatment planning and monitoring are acting as another growth-inducing factor. Apart from this, the integration of artificial intelligence (AI) with MRD testing that helps to identify patterns, predict the likelihood of recurrence, improve the accuracy and effectiveness of diagnosis, and help clinicians to make more informed decisions about patient care, is providing an impetus to the market growth. Additionally, the increasing adoption of NGS technology to determine the sequence of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) to study the genetic variations associated with the disease is creating a positive outlook for the market. Furthermore, growing awareness among people about the importance of identifying the presence of carcinogenic substances that can cause cancer in the body is propelling the market growth. Other factors, including significant growth in the healthcare industry, extensive research and development (R&D) activities, and increasing investments in the field of MRD testing programs, are anticipated to drive the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global minimal residual disease (MRD) testing market, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on technology, application, and end user.

Technology Insights:

Flow Cytometry

Polymerase Chain Reaction (PCR)

Next Generation Sequencing (NGS)

Others

The report has provided a detailed breakup and analysis of the minimal residual disease (MRD) testing market based on the technology. This includes flow cytometry, polymerase chain reaction (PCR), next generation sequencing (NGS) and others. According to the report, polymerase chain reaction (PCR) represented the largest segment.

Application Insights:

Hematological Malignancy

Leukemia

Lymphoma

Solid Tumors

A detailed breakup and analysis of the minimal residual disease (MRD) testing market based on the application has also been provided in the report. This includes hematological malignancy (leukemia and lymphoma) and solid tumors. According to the report, hematological malignancy (leukemia and lymphoma) accounted for the largest market share.

End User Insights:

Hospitals and Speciality Clinics

Diagnostic Laboratories

Academic and Research Institutes

Others

The report has provided a detailed breakup and analysis of the minimal residual disease (MRD) testing market based on the end user. This includes hospitals and speciality clinics, diagnostic laboratories, academic and research institutes, and others. According to the report, hospitals and speciality clinics represented the largest segment.

Regional Insights:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for minimal residual disease (MRD) testing. Some of the factors driving the North America minimal residual disease (MRD) testing market included the increasing prevalence of cancer, significant growth in the healthcare industry, and extensive research and development (R&D) activities.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global minimal residual disease (MRD) testing market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Adaptive Biotechnologies Corporation, Arup Laboratories Inc., Bio-Rad Laboratories Inc., Guardant Health, Invivoscribe Inc., Natera Inc., NeoGenomics Laboratories Inc., Sysmex Corporation, etc.

Key Questions Answered in This Report:

  • How has the global minimal residual disease (MRD) testing market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global minimal residual disease (MRD) testing market?
  • What is the impact of each driver, restraint, and opportunity on the global minimal residual disease (MRD) testing market?
  • What are the key regional markets?
  • Which countries represent the most attractive minimal residual disease (MRD) testing market?
  • What is the breakup of the market based on technology?
  • Which is the most attractive technology in the minimal residual disease (MRD) testing market?
  • What is the breakup of the market based on the application?
  • Which is the most attractive application in the minimal residual disease (MRD) testing market?
  • What is the breakup of the market based on the end user?
  • Which is the most attractive end user in the minimal residual disease (MRD) testing market?
  • What is the competitive structure of the global minimal residual disease (MRD) testing market?
  • Who are the key players/companies in the global minimal residual disease (MRD) testing market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Minimal Residual Disease (MRD) Testing Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Technology

  • 6.1 Flow Cytometry
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Polymerase Chain Reaction (PCR)
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Next Generation Sequencing (NGS)
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Hematological Malignancy
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 Leukemia
      • 7.1.2.2 Lymphoma
    • 7.1.3 Market Forecast
  • 7.2 Solid Tumors
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals and Speciality Clinics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Diagnostic Laboratories
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Academic and Research Institutes
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Adaptive Biotechnologies Corporation
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
    • 14.3.2 Arup Laboratories Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 SWOT Analysis
    • 14.3.3 Bio-Rad Laboratories Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Guardant Health
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
    • 14.3.5 Invivoscribe Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Natera Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
    • 14.3.7 NeoGenomics Laboratories Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
    • 14.3.8 Sysmex Corporation
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Minimal Residual Disease Testing Market: Major Drivers and Challenges
  • Figure 2: Global: Minimal Residual Disease Testing Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Minimal Residual Disease Testing Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Minimal Residual Disease Testing Market: Breakup by Technology (in %), 2023
  • Figure 5: Global: Minimal Residual Disease Testing Market: Breakup by Application (in %), 2023
  • Figure 6: Global: Minimal Residual Disease Testing Market: Breakup by End User (in %), 2023
  • Figure 7: Global: Minimal Residual Disease Testing Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Minimal Residual Disease Testing (Flow Cytometry) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Minimal Residual Disease Testing (Flow Cytometry) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Minimal Residual Disease Testing (Polymerase Chain Reaction (PCR)) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Minimal Residual Disease Testing (Polymerase Chain Reaction (PCR)) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Minimal Residual Disease Testing (Next Generation Sequencing (NGS)) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Minimal Residual Disease Testing (Next Generation Sequencing (NGS)) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Minimal Residual Disease Testing (Other Technologies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Minimal Residual Disease Testing (Other Technologies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Minimal Residual Disease Testing (Hematological Malignancy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Minimal Residual Disease Testing (Hematological Malignancy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Minimal Residual Disease Testing (Solid Tumors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Minimal Residual Disease Testing (Solid Tumors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Minimal Residual Disease Testing (Hospitals and Speciality Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Minimal Residual Disease Testing (Hospitals and Speciality Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Minimal Residual Disease Testing (Diagnostic Laboratories) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Minimal Residual Disease Testing (Diagnostic Laboratories) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Minimal Residual Disease Testing (Academic and Research Institutes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Minimal Residual Disease Testing (Academic and Research Institutes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Minimal Residual Disease Testing (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Minimal Residual Disease Testing (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: North America: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: North America: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: United States: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: United States: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Canada: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Canada: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Asia-Pacific: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Asia-Pacific: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: China: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: China: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Japan: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Japan: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: India: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: India: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: South Korea: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: South Korea: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Australia: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Australia: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Indonesia: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Indonesia: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Others: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Others: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Europe: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Europe: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Germany: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Germany: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: France: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: France: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: United Kingdom: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: United Kingdom: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Italy: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Italy: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Spain: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Spain: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Russia: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Russia: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Others: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Others: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Latin America: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Latin America: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Brazil: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Brazil: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Mexico: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Mexico: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Others: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Others: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Middle East and Africa: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Middle East and Africa: Minimal Residual Disease Testing Market: Breakup by Country (in %), 2023
  • Figure 76: Middle East and Africa: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Global: Minimal Residual Disease Testing Industry: Drivers, Restraints, and Opportunities
  • Figure 78: Global: Minimal Residual Disease Testing Industry: Value Chain Analysis
  • Figure 79: Global: Minimal Residual Disease Testing Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Minimal Residual Disease Testing Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: Minimal Residual Disease Testing Market Forecast: Breakup by Technology (in Million US$), 2024-2032
  • Table 3: Global: Minimal Residual Disease Testing Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 4: Global: Minimal Residual Disease Testing Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 5: Global: Minimal Residual Disease Testing Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Minimal Residual Disease Testing Market: Competitive Structure
  • Table 7: Global: Minimal Residual Disease Testing Market: Key Players